AstraZeneca Gets Imfinzi Boost From CASPIAN Lung Cancer Trial

 
• By Eleanor Malone

Prospects for AstraZeneca’s PD-L1 inhibitor Imfinzi received a welcome boost from an interim analysis of the Phase III study in first-line small-cell lung cancer.

Crocuses
Fresh blooming of Imfinzi’s prospects • Source: Shutterstock

More from Clinical Trials

More from R&D